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Average costs of treating unstable angina were € 2,217 - 3,644 PA. Direct medical costs 
of chronic HF patients were between € 3,150 - 4,792 per patient per year. Average treat-
ment costs for hospitalized PAD in the acute phase were € 4,186 PA, € 2,138 during 
month 1-6 after initial hospitalization, € 1,350 in month 7-12, and € 1,172 in month 
13-18. For stroke, total direct medical costs in year one were € 11,408 per patient. Total 
direct medical costs during the 1st year after an ischemic stroke event were € 15,573 
- 18,517 per patient, € 5,280 in month 13-18, and € 5,479 per year in the subsequent 4 
years. ConClusions: MI, unstable angina, HF, stroke and PAD have a high financial 
impact on the German health care system. Treatment costs in the first year after event 
were highest for MI with € 11,672 – 12,713 per patient followed by stroke with € 11,408 
per patient demonstrating need for improvement in preventing CVE.
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objeCtives: Supraventricular tachycardias (SVT) are a group of arrhythmias which 
result in significant impairment of health-related quality of life (HRQoL). While not 
as common as atrial fibrillation, SVT are still a significant health care problem since 
an average time from the onset of symptoms to successful ablation exceeds 10 years 
both in highly and less developed countries. The aim of this study was to calculate 
an annual cost of conservative treatment of SVT in Poland. Methods: This was 
an economical part of The PPRA study (NCT01594814). PPRA was a single-center, 
prospective, cohort study conducted in tertiary care cardiology center in Poland. All 
data concerning health care resources utilization: outpatient and inpatient visits, 
emergency room (ER) consultations, drugs etc. were derived from the study. Costs of 
disease related groups (DRG), outpatient visits and reimbursed drugs were derived 
from official price lists of Polish National Health Fund (NHF). Costs of ER visits were 
calculated as a mean cost of visit derived from seven hospitals of different levels of 
care. Costs of medical transport were calculated as a mean cost derived from four 
different centers providing ambulance services. Cost of non-reimbursed drugs and 
of outpatient visits and diagnostic tests in private sector were calculated as a mean 
cost of those resources available on official websites of nation-wide providers. All 
costs are presented in Euro (EUR) as median [interquartile range]. Results: During 
1.5 years, 82 patients were enrolled and the data for this analysis was available for all 
patients. The yearly median cost of conservative treatment of SVT was EUR 415 [237-
727] from the NHS perspective and EUR 468 [280-793] from the societal perspective. 
Those costs were mainly driven by costs of hospitalizations and ER. ConClusions: 
Annual cost of conservative treatment of SVT is substantial and driven mainly by 
hospital services.
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objeCtives: The main purpose of study was to evaluate the utilization of implant-
able cardioverter defibrillator (ICD) with or without cardiac resynchronization pacing 
(CRT-D) in Lombardy, the most populated Italian region with universal health care 
coverage for about 10 million inhabitants, from 2000 to 2010. The second aim was 
to assess health care resources utilization after a first ICD implantation, highlight-
ing differences between implant indication (primary and secondary) or ICD type 
(single-chamber, dual-chamber and CRT-D). Methods: Data were extracted from: 
i) the data warehouse DENALI that organizes health care administrative databases 
concerning all subjects covered by Lombardy Health System; ii) ICD National registry 
data. Linking DENALI and registry data, we developed and validated (with Cohen’s 
kappa coefficient) an algorithm to distinguish hospitalizations for ICD in first implant 
and replacement in order to estimate the annual rates of first implant (per million 
person-years) and replacement (per hundred person-years). We selected a cohort 
of patients who underwent a first ICD implantation and we followed them until 
12/31/2010, recording vital status and health care resources consumed: hospitaliza-
tions, drugs and outpatient claims. Results: We identified 25,358 hospitalizations 
for ICD implantation: 17,864 for a first ICD and 8,034 for a replacement. 86% of hospi-
talizations found a match in the National registry and the Cohen’s kappa coefficient 
showed values over 0.8 from 2005. The annual rates were 232.5 (95%CI: 228.5-236.4) 
and 10.5 (95%CI: 10.3-10.7) for first ICD and replacement respectively. We selected a 
cohort of 12,525 patients who underwent a first ICD: 55% were implanted in primary 
prevention and the ICD types were: 35% single-chamber, 29% dual-chamber and 35% 
CRT-D. Among these groups, we detected differences in survival, ICD duration and 
health care resources utilization. ConClusions: The combined use of information 
from national ICD registry and health care administrative databases could overcome 
the limitation of both data sources and it could improve the monitoring of ICD therapy.
PCV77
does A 12-leAd eCg more reliAbly deteCt AtriAl fibrilAtion thAn A 
rhythm striP only eCg?
Vyas V., Duran J., Ansaripour A., Niedzielko M., Steel A., Bakhai A.
Barnet & Chase Farm Hospitals NHS Trust, London, UK
objeCtives: The 12-lead electrocardiogram (ECG) is the current gold standard for 
the diagnosis of atrial fibrillation (AF). However, undertaking a 12-lead ECG is cum-
bersome, expensive and time consuming compared to a rhythm strip alone. The AF 
detection rate using a single lead ECG compared with a12-lead ECG amongst trainees 
of varying degrees of experience has not yet been reviewed in depth. Methods: 
Five doctors of different grades and specialties and one Cardiology Specialist Nurse 
sion models for costs and LOS used log transformation techniques. Results: A total 
of 62,527 patients (8,800 Bleeding; 53,727 Non-Bleeding) were included. Patients who 
received blood/blood products were significantly different in a number of baseline 
characteristics including Charlson Comorbidity Index. Unadjusted outcomes dem-
onstrated significant differences in mean total costs ($43,375 Bleeding; $18,411 Non-
Bleeding; p< 0.001) and LOS (13.62 Bleeding; 7.53 Non-Bleeding; p< 0.001) for patients 
who received blood products compared with those who did not. Multivariate models 
adjusting for patient characteristics demonstrated that patients who received blood/
blood products had 38.9% greater LOS and 34.3% greater ICU LOS. They also were 
3.53 times as likely to be admitted to the ICU, 3.75 times as likely to be readmitted 
for bleeding and 4.09 times as likely to die in hospital (all p< 0.001). Furthermore, 
they had 32.9% greater total cost of care including blood product cost and 31.8% 
greater total cost of care excluding blood product cost (both p< 0.001). ConClusions: 
Preventing or rapidly controlling emergent bleeding in trauma patients would likely 
reduce patient risk and avoid elevated costs of hospitalization.
PCV71
the eConomiC imPACt of hyPertension in heAlth CAre system of 
PAkistAn
Iqbal M.S.1, Iqbal M.W.2, Bahari M.B.B.1, Iqbal M.Z.1
1Department of Clinical Pharmacy, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 
2Faculty of Law, Universiti Malaya,, Kualalumpur, Malaysia
objeCtives: Hypertension (HTN) is a severe public health issue across the globe 
and a major risk factor for various cardiovascular diseases. This study was aimed 
to examine the potential costs of prognostic utilities and direct and indirect 
health care costs of the treatment of HTN in patients visiting public hospitals in 
Pakistan. Methods: A cross-sectional, convenient-sampling oriented study was 
conducted in patients attending public hospitals in Pakistan. The direct and indi-
rect health care costs were assessed by different variables i.e. consultation fees, 
cost of medicines, travelling costs, laboratory test expenses. All obtained data were 
analyzed using descriptive and inferential statistics. Results: The mean annual 
direct health care cost for a HTN patient was around PKRs. 19789.88 (US$ 201.21) 
and indirect health care cost was PKRs. 11990.90 (US$ 121.92). It was also observed 
that the mean indirect health care costs per patient were significantly varied 
(p < 0.001) among different public hospitals. ConClusions: Type of the HTN, dis-
tance to the hospital and length of stay in the hospital were proportional to the 
direct and indirect health care costs of the HTN patients. Better management of 
HTN can favorably impact the disease burden as untreated HTN or its comorbidi-
ties increase the overall treatment costs which affect affordability of the patient.
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objeCtives: Advances in the prevention and treatment of ischemic stroke and 
transient ischemic attack (TIA) during the past two decades have resulted in changes 
of medical practice. However, the existing cost estimates of ischemic stroke and 
TIA are based on resource use and cost data of approximately 20 years ago. We 
therefore determined hospital costs of ischemic stroke and TIA in the Netherlands 
for 2012. Methods: A retrospective cost analysis was conducted using patient 
and resource use data from the Diagnosis Treatment Combination (Diagnose 
Behandeling Combinatie) casemix system. Four subgroups were analysed: inpa-
tient ischemic stroke, inpatient TIA, outpatient ischemic stroke, and outpatient TIA. 
Additionally, we estimated the costs for carotid endarterectomy. Unit costs were 
based on 2012 reference prices of the Dutch Manual of Costing and tariffs provided 
by the Dutch Healthcare Authority. Ordinary least squares regression analysis was 
used to examine the association between hospital costs and various patient and 
hospital characteristics. Results: A total of 35,903 ischemic stroke and 21,653 TIA 
patients were included. Inpatient care costs for ischemic stroke were € 5,328 while 
the costs for TIA were € 2,470. Outpatient costs were estimated at € 495 for ischemic 
stroke and € 587 for TIA. Average hospital costs for carotid endarterectomy were 
estimated at € 6,836. The number of inpatient days was the greatest contributor 
to hospital costs for ischemic stroke and TIA patients. Age, type of hospital, and 
region were strong predictors of hospital costs. ConClusions: This study is the 
most recent and extensive cost analysis of inpatient and outpatient hospital costs 
of ischemic stroke and TIA patients. Our results may be used as input for economic 
evaluations and health economic models to support decision making about reim-
bursement, investment, and pricing of health care interventions.
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objeCtives: Cardiovascular events (CVE) are the number one cause of death (42%) 
in Germany. This study evaluates available literature regarding direct medical costs 
related to CVE in Germany. The CVE of interest were myocardial infarction (MI), unsta-
ble angina, heart failure (HF), stroke, and peripheral artery disease (PAD). Update of a 
review conducted in 2012. Methods: A systematic literature search was performed 
in the following databases- Medline, Embase, Centre for Reviews and Dissemination, 
TIBORDER, and German dissertation database from 01/2003 to 10/2013. Observational 
studies and randomized clinical trials were considered for the review. Results: The 
search identified 400 publications; 13 were included in this review. For MI, average hos-
pitalization costs during acute phase were between € 5,836 and € 7,522 per admission 
(PA). In the first year after a MI, direct medical costs were € 11,672 - 12,713 per patient. 
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clinical response to treatment and the number of QALYs per patient accrued during 
the study. Only direct medical costs (drug acquisition, administration and hospitali-
zation costs) were incorporated in the model, as the analysis was conducted from a 
third-party payer perspective. With respect to administration cost, two alternative 
scenarios were considered in the base case analysis: administration in day-case unit 
and administration in the hospital outpatient department. Probabilistic sensitivity 
analysis was conducted. Primary outcomes were quality adjusted life years (QALYs) 
and incremental cost-effectiveness ratios (ICER). Results: In the base case analysis, 
QALYs of FCM treated patients were higher compared to no iron treated patients by 
0.04 QALYs. The total 24-week cost of FCM was higher by € 969 and € 204, it the two 
scenarios respectively. This difference was mainly attributed to the administration 
cost and drug acquisition cost related to FMC. Incremental cost effectiveness analysis 
showed that treatment with FCM was a cost-effective option resulting in an ICER 
of € 25,506 and € 5,368 per QALY gained in the scenarios respectively. Probabilistic 
sensitivity analysis revealed that FCM was likely to be cost-effective in over 80% and 
99% in the two scenarios respectively, at a willingness-to-pay threshold of € 34,000 
per QALY gained. ConClusions: Ferric carboxymaltose may be a cost – effective 
option in relation to no iron treatment for the management of iron deficiency of HF 
patients in Greece.
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objeCtives: Non-adherence to drug therapy poses a significant problem in the treat-
ment of patients with presumed resistant hypertension (RH). It has been shown that 
therapeutic drug monitoring (TDM) is a useful tool for detecting non-adherence and 
identifying barriers to treatment adherence, leading to effective blood pressure (BP) 
control. However, the cost-effectiveness of TDM in the management of RH has not 
been investigated. Methods: A Markov model was used to evaluate life-years, qual-
ity-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in RH 
patients receiving either TDM optimized therapy or standard best medical therapy. 
The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. 
Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and 
mortality. Cost analyses were performed from a payer’s perspective. Deterministic 
and probabilistic sensitivity analyses were conducted. Results: In the age group 
of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at addi-
tional costs of € 3,854 and € 3,922, respectively. Given a willingness-to-pay threshold 
of € 35,000 per QALY gained, the probability of TDM being cost-effective was ≥ 95% in 
all age groups from 30 to 90 years. Results were influenced mostly by the frequency 
of TDM testing, the rate of non-responders to TDM, and the magnitude of effect of 
TDM on BP. ConClusions: Therapeutic drug monitoring presents a potentialy highly 
cost-effective health care intervention in patients diagnosed with RH. Importantly, 
this finding is valid for a wide range of patients, independent of gender and age.
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objeCtives: SHIFT trial demonstrated that, by decreasing heart rate with 
Ivabradine, the incidence of events is reduced in patients with HF due to left ven-
tricular systolic disfunction (LVSD) and heart rate (HR) over 70 bpm. A cost-effective-
ness analysis demonstrating that this treatment strategy is cost-effective in United 
Kingdom has been published, but there are no publications with Spanish data. The 
objetive of this analysis is to determine whether treatment with Ivabradine in HF 
due to LVSD is a cost-effective strategy in Spain. Methods: A Markov model with 
three health states was built (baseline, admission due to HF and death), based on a 
simulated cohort of patients suffering HF due to LVSD and HR over 70 bpm, in order 
to compare the treatment strategies of the SHIFT trial, Ivabradine vs placebo, on top 
of standard treatment, was performed. A cost-efectiveness analysis with a life-time 
horizon, under the perspective of the NHS. Spanish costs were used to feed the 
model, and it was assumed that quality of life was worse during hospitalizations. 
A probabilistic sensitivity analysis was performed. The model took into account 
the incidence of complications related with HF (admission for HF, readmission for 
HF and death) and was fed with transition probabilities taken from the SHIFT trial 
and the SHIFT-hospitalization trial. Costs were obtained from cost data bases, the 
National Statistics Institute of Spain, institutions and scientific journals. Results: 
Cost per QALY of Ivabradine in comparison to placebo in heart failure due to left 
ventricular systolic disfunction is € 17,488 € , well below the acceptability threshold 
accepted in our enviroment (around 30,000 € ). Cost per LYG was € 13,044. Results 
were robust in the performed sensitivity analyses. ConClusions: In conclusion, 
treatment with Ivabradine in heart failure due to left ventricular systolic dysfunc-
tion is cost-effective in Spain.
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objeCtives: The objective of this study was to evaluate the cost-effectiveness 
of apixaban in the prevention of thromboembolic events in patients with non-
valvular atrial fibrillation (NVAF) relatively to standard of care (warfarin or aspirin) 
from the Italian National Health System (SSN) perspective. Methods: A previ-
ously published Markov model was adapted for Italian NVAF patients. Clinical 
were each asked to review a different batch of ECGs with differing proportions of AF 
and Sinus Rhythm (SR). ECGs were presented to the reviewers on two separate occa-
sions in two variations: full 12 lead and 10-second rhythm strip only. The diagnoses 
(AF/SR or unsure) were compared to a Consultant Cardiologist reading the 12-lead 
ECG. Results: Overall, compared to the Consultant Cardiologist, the AF detection 
rate using a 12-lead ECG was 81% and 82% with a rhythm strip. There was a signifi-
cant difference (chi squared test, p< 0.01) in AF detection rate when the reviewers 
were divided into 2 groups according to level of cardiology experience. The AF detec-
tion rate for the 12-lead ECG amongst specialists vs. non-specialists was 93% vs. 
70% (P< 0.001) and 92% vs. 73% (P= 0.003) for the rhythm strip. ConClusions: Our 
findings indicate that a 10-second rhythm strip alone has a comparable AF detection 
rate to a 12-lead ECG in the hands of doctors and nurses when measured against the 
consultant’s diagnosis. With both the rhythm strip and a 12-lead ECG, the accuracy 
of AF detection improved with experience. Mass screening using a single strip could 
be acceptable and inexpensive particularly with mobile phone technology.
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objeCtives: Hemostatic agents are used to stop intraoperative bleeding in the 
presence of actively flowing blood when applied directly to the bleeding site. Recent 
published literature on animal studies and real-world outcome data indicated that 
the hemostatic matrix agent Floseal could stop bleedings and reduce complications 
more effectively than Surgiflo with thrombin. The objective of this study is to quan-
tify cost consequences in the Netherlands when using Floseal versus Surgiflo with 
thrombin from a hospital perspective. Methods: A cost-consequence model was 
built based on a large retrospective analysis of a Premier’s US Hospital database to 
assess the value of using Floseal to achieve hemostasis in mixed cardiac surgery pro-
cedures relative to Surgiflo with thrombin. The model captures the cost implications 
on the following parameters: (1) operating room time; (2) postoperative bleeding-
related complication rates; (3) the need for surgical revisions due to bleeding, and; 
(4) the number of intraoperative and postoperative blood transfusions. Costs (€ ) 
were derived from published literature, the Dutch guideline for cost research and 
2014 national list prices. The model assumed a surgical case load of 100 mixed 
cardiac surgeries. Results: By reducing operating time, but moreover the number 
of complications, surgical revisions and blood products transfusion, Floseal can 
lead to a cost saving of € 2,933 per patient in comparison to the use of Surgiflo with 
thrombin. ConClusions: Our preliminary analysis indicates that using Floseal to 
stop intraoperative bleeding could lead to significant cost saving for the hospitals in 
the Netherlands. Further studies are required to confirm these findings.
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objeCtives: To evaluate cost-effectiveness of dabigatran and new oral antico-
agulants (NOA) compared to currently reimbursed warfarin and low molecular 
weight heparins (LMWH) for thromboembolic events prophylaxis from a payer’s 
perspective in Colombia. Methods: Markov decision model based on efficacy, 
utilities and safety inputs from clinical trials (CT) (RE-COVER I and II; Einstein-
DVT; Einstein-PE; AMPLIFY; RE-SONATE; RE-MEDY and a meta-analysis of 18 CT 
for LMWH. Cost of medication was obtained from SISMED, Vademecum Med®, 
and government reference prices; costs of events were estimated from hospital 
billing records, POS tariffs, SOAT Manual and local experts. Costs are reported in 
euros (1 € = COP 2,655) and effectiveness in terms of deaths due to bleeding and 
Quality Adjusted Life Years (QALYs). A 3% discount rate was used for costs and 
QALYs. A cohort of 1,000 patients, with similar demographic characteristics to 
those reported in the CT, was followed for a 5-year time horizon; with analysis for 6 
months, 1 year and lifetime. A univariate and probabilistic sensitivity analysis was 
performed. Results: Deaths due to bleeding were 5 with dabigatran, 7 with apixa-
ban, 9 with LMWH, 7 with rivaroxaban and 15 with warfarin, per 10,000 patients. 
Dabigatran is dominant compared with LMWH and apixaban. Compared with 
rivaroxaban, dabigatran is safer with similar costs and QALYs gained. Considering 
a base line scenario comparing all alternatives versus warfarin, dabigatrán dem-
onstrates the lowest ICER (€ 32,121/QALY) compared with rivaroxaban (€ 36,388/
QALY), apixaban (€ 72,228/QALY) and LMWH (€ 604,515/QALY). Our findings were 
consistent in the sensitivity analyses. ConClusions: Dabigatran is the alter-
native with the best value for money when all alternatives are compared with 
warfarin, and is dominant compared with LMWH, which are reimbursed by the 
current Colombian National Plan POS.
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objeCtives: To evaluate the cost-effectiveness of iron repletion with ferric carboxy-
maltorse (FCM), in iron-deficient heart failure (HF) patients in Greece. Methods: 
An international economic model was locally adapted to evaluate the use ferric car-
boxymaltorse to standard care over a time horizon of 24 weeks corresponding to the 
duration of the FAIR-HF trial. The efficacy of therapy was evaluated based on the 
